Danaher Co. (NYSE:DHR) Stock Position Lowered by WealthBridge Investment Counsel Inc.

WealthBridge Investment Counsel Inc. trimmed its position in shares of Danaher Co. (NYSE:DHR) by 1.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,460 shares of the conglomerate’s stock after selling 250 shares during the period. WealthBridge Investment Counsel Inc.’s holdings in Danaher were worth $4,298,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Oak Thistle LLC purchased a new stake in Danaher in the 2nd quarter worth about $363,000. HighPoint Advisor Group LLC acquired a new stake in shares of Danaher during the fourth quarter worth approximately $2,614,000. Norden Group LLC purchased a new position in Danaher during the first quarter valued at approximately $4,151,000. Duality Advisers LP acquired a new position in Danaher in the 1st quarter valued at approximately $5,573,000. Finally, Investment Research & Advisory Group Inc. acquired a new stake in shares of Danaher during the 1st quarter valued at $1,186,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DHR has been the subject of several recent research reports. Wells Fargo & Company began coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Danaher in a research note on Friday, September 6th. Evercore ISI increased their price target on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Stephens initiated coverage on shares of Danaher in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $282.12.

Insider Activity

In other news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 in the last quarter. Corporate insiders own 11.10% of the company’s stock.

Danaher Price Performance

Danaher stock opened at $266.45 on Friday. The stock has a market cap of $192.43 billion, a price-to-earnings ratio of 47.33, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The business’s 50-day simple moving average is $270.73 and its 200 day simple moving average is $258.92.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.05 earnings per share. As a group, research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.41%. Danaher’s dividend payout ratio is 19.18%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.